Suggestions appear as you type. Use the up and down arrows to choose one and Enter to open it.

This page's audience our own tag's counts — open to see them
–Visits
–Page views
–Clicks to vendors
–Time on page
–Reading now
Clicks to vendors, by tool
  • –
Top countries
  • –
Devices
  • –

– · visits, page views and clicks counted by our own tag, which counts more than our checked analytics; every figure rounded down · how we count

emba review

Free#37 of 37 in Static Analysis Tools

A focused cancer-biomarker analysis package, not a source-code static analyzer.

5.7/10Editor score
Visit emba
emba5.7 Visit emba

Reviewed by iTechGuides Editors · Editorial team · Updated Oct 2026

emba is an open-source R package for analyzing and visualizing ensembles of Boolean models used in cancer-cell-network biomarker discovery. It is intended for researchers who need to compare model behavior, examine predictive or synergy-related groupings, and identify biomarkers from simulation results. The package is distributed through CRAN and GitHub and is maintained by John Zobolas, giving research teams a code-based option for this specialized workflow.

Its analytical scope is specific and clearly defined. emba can load simulation results from the DrugLogics pipeline, group models by true-positive or Matthews correlation scores, and group them by synergy predictions against gold-standard synergies. It also calculates average activity differences between model groups and identifies synergy, performance, and link-operator biomarkers using user-defined thresholds. Visualization features help present Boolean-model ensemble analysis results, while the DrugLogics integration connects the package to that simulation pipeline.

The main consideration is category fit. emba addresses biological model analysis rather than inspection of application source code, so teams seeking security checks, code-quality rules, defect detection, or broader developer-tool integrations should choose a dedicated static analysis product instead. Its narrow focus is appropriate for researchers working with Boolean models and biomarker discovery, but less suitable for general software engineering teams. Documentation and community support are available, and the open-source distribution allows qualified users to work directly with the package in an R environment.

emba pros and cons

  • Where it wins
    • Analyzes Boolean-model ensembles for biomarker discovery
    • Visualizes ensemble results and groups models by predictive scores
    • Loads simulation results from the DrugLogics pipeline
  • Where it doesn't
    • Does not perform source-code static analysis
    • Focused on Boolean-model biomarker research rather than general development
    • Support is limited to documentation and community channels

emba fact sheet, pricing and score →

Advertiser disclosure: iTechGuides is reader-supported. Vendors can pay for top positions in our rankings and for a place on other products' pages, and we may earn a commission when you click some links. Bought places stand at the number bought; this page and our disclosure say so. Paying vendors may get a fuller, more detailed review from our editors, and that review can change their score. How we rank.

Last updated · How we research and update